Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Equity Income (2020 - 2024)

Historic Equity Income for Sutro Biopharma (STRO) over the last 5 years, with Q2 2024 value amounting to $4.8 million.

  • Sutro Biopharma's Equity Income fell 4221.85% to $4.8 million in Q2 2024 from the same period last year, while for Mar 2025 it was $4.8 million, marking a year-over-year decrease of 7664.66%. This contributed to the annual value of $9.9 million for FY2023, which is 1824.4% down from last year.
  • Sutro Biopharma's Equity Income amounted to $4.8 million in Q2 2024, which was down 4221.85% from $3.7 million recorded in Q1 2024.
  • Over the past 5 years, Sutro Biopharma's Equity Income peaked at $48.9 million during Q2 2020, and registered a low of -$37.1 million during Q4 2020.
  • For the 5-year period, Sutro Biopharma's Equity Income averaged around $4.0 million, with its median value being $3.7 million (2024).
  • Its Equity Income has fluctuated over the past 5 years, first soared by 55888.07% in 2022, then tumbled by 134191.83% in 2023.
  • Sutro Biopharma's Equity Income (Quarter) stood at -$37.1 million in 2020, then skyrocketed by 93.07% to -$2.6 million in 2021, then surged by 558.88% to $11.8 million in 2022, then crashed by 33.14% to $7.9 million in 2023, then crashed by 39.09% to $4.8 million in 2024.
  • Its Equity Income was $4.8 million in Q2 2024, compared to $3.7 million in Q1 2024 and $7.9 million in Q4 2023.